Armata completes enrollment of Phase 1b/2a diSArm study of AP-SA02 for S. aureus bacteremia; topline Q1 2025

Armata Pharmaceuticals, Inc.

Full enrollment (n=50) achieved for intravenous AP-SA02 in Phase 1b/2a diSArm study targeting Staphylococcus aureus bacteremia.
Topline data expected in Q1 2025; if positive, may support initiation of a pivotal efficacy trial later in 2025.
Dose escalated to 5E10 PFU every 6 hours (2E11 PFU/24h) for 5 days without clinically significant adverse events.
Two blinded subsets observed: one showing evidence of in vivo phage amplification with detectable phage in blood.
Study supported by $21.6M in funding from Defense Health Agency and Joint Warfighter Medical Research Program via MTEC and NMRC-NAMD.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.